Mr. Speaker, there are important life-saving drugs that Canadians might not be able to access in a timely manner. Some Canadians are suffering from serious conditions and cannot access proven life-saving drugs. We know the risks, and we know the science behind these drugs is sound. Those are not the problems. The problems facing Canadians trying to access life-saving drugs are too much paperwork and too much bureaucracy. That is why we are debating Bill C-265 today, so we can get life-saving drugs to Canadians who need them in a timely and efficient manner.
This is an act to amend the Food and Drugs Act. To be more clear, it is meant to provide a list of therapeutic products pre-approved for special access. “Pre-approved” is the key word. Pre-approved drugs cut down on time and bureaucracy. Canada already has a program designed for Canadians with serious or rare conditions when no other treatments exist. It is called the special access program. The problem is that there are no provisions for pre-approved drugs that are based on precedent. The special access program was meant to open a door to therapies already proven to be effective elsewhere. The intent was there, the intent was good, but the implementation failed.
In 2025 alone, over 11,000 requests were processed, but each request was treated as a new request. Repeated requests were treated as new requests, instead of a consistent and efficient system that recognized the suffering and complications that some Canadians were experiencing. These are drugs requested before by Canadian doctors, drugs approved by jurisdictions that we consider to be our peers and drugs with real-world data behind them, yet each application started from scratch. Not only do doctors have to go through this process time and time again, but the patients also have to apply time and time again.
My own brother, who suffers from a rare spinal disease, had to go through this for years. When his medications ran out, he would have to wait for his application to be approved so he could resume pain management. This left a gap. This left him to self-medicate with non-prescription drugs, which he hated to do, but he could not bear the pain, and I do not blame him. How many other people have considered this option? If the special access program was streamlined for well-established use cases, people like my brother would have less pain and definitely less stress, especially when the drug is referred to as “life-saving”. The paperwork and bureaucracy do not produce or generate new data. They do not generate new knowledge, but they take up time. For patients with serious conditions, time is a valuable commodity.
There is no doubt that the Conservatives support this bill, but there are problems with it. My time is limited, so I will not go through them, but many of my colleagues have pointed out the problems with the bill. It is our wish that this bill go to committee.
One of the problems is that the bill, as presented, would open the door for dangerous drugs to make it onto the pre-approved list and would effectively create a loophole that would make it easy for people suffering from drug use to be prescribed methamphetamine as liquid caffeine. This is far from being hypothetical. Through the special access program, requests for drugs like LSD and MDMA have in fact been made.
Members may also recall that restrictions on the special access program existed to limit opioid diversion under the Harper government. In 2013, then health minister Rona Ambrose amended the program after learning that Health Canada had approved a request granting 21 patients with chronic addictions access to prescription heroin. However, the Trudeau Liberal government later lifted the restrictions that Conservatives had imposed on illegal and harmful substances, such as LSD, heroin and cocaine. Conservatives had put those restrictions in there for a reason.
We look forward to seeing this go to committee for more amendments.